IR Playbook pp 331-340 | Cite as

Aortoiliac Disease

  • Alok B. Bhatt
  • James F. BenenatiEmail author


Peripheral arterial disease (PAD) is increasingly prevalent but remains underdiagnosed and undertreated. The clinical significance of PAD spans beyond the symptoms it causes—rather, it is due to its associated cardiovascular morbidity and mortality. With respect to symptomology, the clinical manifestations of PAD will vary based on severity and anatomic distribution disease. The following chapter will focus on recognizing aortoiliac disease and will present a framework by which aortoiliac disease can be managed.


Aortoiliac occlusive disease Peripheral arterial disease Claudication Critical limb ischemia Angioplasty Stent 


  1. 1.
    Fowkes FG, Rudan D, Rudan I, Aboyans V, Denenberg JO, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet. 2013;382(9901):1329–40. Scholar
  2. 2.
    Olin JW, White CJ, Armstrong EJ, Kadian-Dodov D, Hiatt WR. Peripheral artery disease. J Am Coll Cardiol. 2016;67(11):1338–57. Scholar
  3. 3.
    Aboyans V, Desormais I, Lacroix P. The general prognosis of patients with peripheral arterial disease differs according to the disease localization. J Vasc Surg. 2010;51(6):1585–6. Scholar
  4. 4.
    McDermott MM, Greenland P, Liu K, Guralnik JM, Criqui MH, Dolan NC, et al. Leg symptoms in peripheral arterial disease: associated clinical characteristics and functional impairment. JAMA. 2001;286(13):1599–606. Scholar
  5. 5.
    Abu Dabrh AM, Steffen MW, Undavalli C, Asi N, Wang Z, Elamin MB, et al. The natural history of untreated severe or critical limb ischemia. J Vasc Surg. 2015;62(6):1642–51. Scholar
  6. 6.
    Crawford JD, Perrone KH, Wong VW, Mitchell EL, Azarbal AF, Liem TK, Moneta GLA. Modern series of acute aortic occlusion. J Vasc Surg. 2014;59(4):1044–50. Scholar
  7. 7.
    Okazaki J, Guntani A, Homma K, Kyuragi R, Kawakubo E, Maehara Y. Fibromuscular dysplasia of the lower extremities. Ann Vasc Dis. 2011;4(2):143–9. Scholar
  8. 8.
    Chi Y. Safety and efficacy of cilostazol in the management of intermittent claudication. Vasc Health Risk Manag. 2008;4:1197–203. Scholar
  9. 9.
    Neisen M. Endovascular management of aortoiliac occlusive disease. Semin Interv Radiol. 2009;26(04):296–302. Scholar
  10. 10.
    Jaff MR, White CJ, Hiatt WR, Fowkes GR, Dormandy J, et al. An update on methods for revascularization and expansion of the TASC lesion classification to include below-the-knee arteries: a supplement to the inter-society consensus for the management of peripheral arterial disease (TASC II): the TASC Steering Committee. Catheter Cardiovasc Interv. 2015;86(4):611–25. Scholar
  11. 11.
    Bosiers M, Deloose K, Callaert J, Maene L, Beelen R, Keirse K, et al. BRAVISSIMO: 12-month results from a large scale prospective trial. J Cardiovasc Surg. 2013;54(2):235–53.Google Scholar
  12. 12.
    Lee HJ, Armstrong E, Salhan N, Realyvasquez AJ, Laird JR, Humphries M. Patency of the internal iliac artery after placement of common and external iliac artery stents. J Vasc Surg. 2015;61(6). Scholar
  13. 13.
    Aggarwal V, Waldo S, Armstrong E. Endovascular revascularization for aortoiliac atherosclerotic disease. Vasc Health Risk Manag. 2016;12:117–27. Scholar
  14. 14.
    Renshaw A, Mccowen T, Waltke EA, Wattenhofer SP, Tahara RW, Baxter BT. Angioplasty with stenting is effective in treating blue toe syndrome. Vasc Endovasc Surg. 2002;36(2):155–9. Scholar
  15. 15.
    Matchett WJ, Mcfarland DR, Eidt JF, Moursi MM. Blue toe syndrome: treatment with intra-arterial stents and review of therapies. J Vasc Interv Radiol. 2000;11(5):585–92. Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Interventional RadiologyMiami Cardiac and Vascular Institute, Baptist Hospital of MiamiMiamiUSA

Personalised recommendations